Quantcast
Last updated on April 18, 2014 at 10:25 EDT

Latest Pulmonology Stories

2013-04-25 08:35:58

CHEST JOURNAL TO PUBLISH ARTICLE FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION IN JULY ISSUE AND ONLINE NORTHBROOK, Ill., April 25, 2013 /PRNewswire-USNewswire/ -- An updated analysis from the Centers for Disease Control and Prevention (CDC) reports a decrease in deaths among male patients who have chronic obstructive pulmonary disease (COPD) and a decline in hospitalizations for patients with COPD. The report also reveals that rates of physician-based office and emergency...

2013-04-19 17:59:57

Baylor College of Medicine researchers will lead a three-year, $4.2 million study funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to determine whether drugs called beta blockers can ease airway narrowing in patients with asthma and examine potential mechanisms. Researchers from Duke University in Durham, North Carolina, and Washington University in St. Louis, Missouri, also will participate. "Previously, beta...

2013-04-17 16:26:46

LONDON and SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted that the efficacy and safety data provide substantial evidence to support approval of BREO(TM) ELLIPTA(TM) as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic...

2013-04-17 14:57:03

A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis, a rare and devastating lung disease, found multiple genetic associations with the disease, including one gene variant that was linked to an increase in the risk of death. The study, released early online in The Lancet Respiratory Medicine, showed that a variant in a gene called TOLLIP was associated with an increased mortality risk. That variant resulted in decreased expression of TOLLIP in...

2013-04-17 08:29:39

BRISBANE, Calif., April 17, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its first quarter 2013 financial results at the close of the U.S. markets on Wednesday, April 24, 2013. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day. (Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO) Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or...

2013-04-15 08:29:30

--ASM-024 has a novel mechanism with multifunctional properties at the nicotinic and muscarinic levels-- QUEBEC CITY, Canada, April 15, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, announced the start of a phase 1/2 clinical trial of its lead compound, ASM-024, in a dry powder for inhalation (DPI) formulation. The...

2013-04-12 13:09:16

Researchers from Boston University School of Medicine (BUSM) have pinpointed a genetic signature for chronic obstructive pulmonary disease (COPD) from airway cells harvested utilizing a minimally invasive procedure. The findings provide a novel way to study COPD and could lead to new treatments and ways to monitor patient's response to those treatments. The study is published online in the American Journal of Respiratory and Critical Care Medicine. Chronic obstructive pulmonary disease...

2013-04-09 08:31:40

Surveyed Payers Expect to Restrict the Prescribing of Emerging Biologics Through Controls Similar to Xolair, Limiting Patient Access, According to a New Report from Decision Resources BURLINGTON, Mass., April 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. pulmonologists estimate that only 19 percent of their severe, refractory asthma patients are treated with...

2013-04-01 23:01:12

New program offers hope to people with Chronic Respiratory Diseases. New York, NY (PRWEB) April 01, 2013 The Pulmonary Wellness & Rehabilitation Center has partnered with the American Lung Association to bring its renowned Better Breathers Club to New York City. Better Breathers Clubs are support groups for those who suffer from chronic pulmonary diseases including Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis and Pulmonary Fibrosis, among many...

2013-03-29 08:21:50

WARRINGTON, Pa., March 29, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to SURFAXIN(®) (lucinactant) Intratracheal Suspension. SURFAXIN, currently the only FDA approved synthetic alternative to animal-derived surfactants in the U.S., was highlighted in the December issue of the Journal of Pediatric...


Latest Pulmonology Reference Libraries

0_f9fe10c6664d20ba0d9091907b66a65f
2011-01-05 16:00:36

Human parainfluenza viruses, belonging to the paramyxovirus family, are a group of four distinct serotypes of enveloped single-stranded RNA viruses. They are the second most common cause of lower respiratory tract infection in younger children. Many times the host has repeat infections throughout life with symptoms that may include upper respiratory tract illness or more commonly, a cold and sore throat. It can also cause severe pneumonia in immunosuppressed people. There is currently no...

More Articles (1 articles) »